Acute Lymphocytic Leukemia
Conditions
Keywords
Refractory or Relapsed Acute Lymphocytic Leukemia
Brief summary
This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum tolerated dose (MTD) of liposomal annamycin and to evaluate the safety of liposomal annamycin in patients with refractory or relapsed acute lymphocytic leukemia.
Detailed description
This is a Phase I/II, multi-center, open-label, dose escalation, MTD study of liposomal annamycin in refractory or relapsed ALL patients. Enrollment will occur in cohorts of approximately 3 patients with 10 additional patients enrolled at the MTD. The liposomal annamycin doses will be escalated in sequential cohorts. Four dose levels of liposomal annamycin are planned: 190, 230, 280, and 310 mg/m2/day.
Interventions
3-day IV infusion
Sponsors
Callisto Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of refractory or relapsed ALL (acute lymphocytic leukemia) * Age greater than or equal to 15 years * No chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and recovered from toxic side effects of that therapy, unless treatment is indicated due to progressive disease. * No investigational therapy within 4 weeks of first dose of study drug * ECOG performance status (PS) 0 to 2. * Adequate liver function * Adequate renal function * Signed informed consent
Exclusion criteria
* Concommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system \[CNS\] therapy) * Any condition which in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study. * Cardiac ejection fraction less than 40% * Clinically relevant serious co-morbid medical conditions. * Pregnant, lactating or not using adequate contraception. * Known allergy to doxorubicin or anthracyclines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of L-Annamycin | 8 months |
| MTD | 8 months |
Secondary
| Measure | Time frame |
|---|---|
| To study multi drug-resistant (MDR)-1 encoded P-170 glycoprotein expression and MDR-1 multidrug-resistant-associated protein (MRP), lung-resistance associated protein LRP), and breast cancer resistance protein (BCRP) mRNA levels | 8 months |
| To measure the pharmacokinetics of annamycin and its metabolite, annamycinol. | 8 months |
Countries
United States
Contacts
Primary ContactCraig C. Talluto, PhD, abd
Outcome results
None listed